<DOC>
	<DOCNO>NCT00751478</DOCNO>
	<brief_summary>The purpose study determine relative pharmacodynamic effect safety crush whole ALO-01 compare MSIR Placebo , crush ALO-01 whole ALO-01 ; determine relative bioavailability plasma morphine crush whole ALO-01 compare MSIR , crush ALO-01 whole ALO-01 ; determine relative bioavailability plasma naltrexone 6-Î²-naltrexol crush ALO-01 whole ALO-01 .</brief_summary>
	<brief_title>Study Determine Bioavailability , Pharmacodynamic Effects , Safety Whole Crushed ALO-01 Compared Morphine Sulfate Immediate Release ( MSIR )</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Male female subject 18 55 year age , inclusive . Subjects opioid user currently physically dependent opioids ( base DSMIV criterion ) experience use opioids nontherapeutic purpose ( i.e . psychoactive effect ) least 10 occasion within last year least 12 week prior screen session . Subjects healthy indicated medical history , physical examination , vital sign , oxygen saturation , clinical laboratory test , 12lead ECG perform screen session . Subjects consent use two medically acceptable method contraception throughout entire study period , include washout period , female one week study complete . Female subject negative serum pregnancy test screen negative urine pregnancy test prior qualify session treatment session , lactate . Subject willing able remain study unit entire duration confinement period return study site outpatient visit . Subjects positive urine drug screen opiate , amphetamine , cocaine benzodiazepine screen could enroll , provide test negative substance qualify treatment session clinically observe sign symptom drug withdrawal . Subjects positive urine screen tetrahydrocannabinol ( THC ) screening could enrol , provide THC level stable decrease subsequent drug screen ( prior qualify treatment session ) . Subjects body mass index ( BMI ) within range 2131 kg/m2 weight great 55 kg , inclusive . Subjects voluntarily consent participate study , provide write informed consent prior commencement studyspecific procedure understand free withdraw study time . Subjects exclude study : With history presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic psychiatric disease condition , , opinion investigator , would jeopardize safety subject validity study result . With history clinically significant brain condition ( e.g. , neoplasms , cerebrovascular disease , history stroke , syncope , infectious disease significant head trauma ) currently treat medication treatment regimens low seizure threshold . With history presence drug alcohol dependence exclude nicotine caffeine . This included subject ever drug rehabilitation program . Who current psychiatric illness , except nicotine dependence . Subjects past history psychiatric illness could exclude discretion Investigator designee . Who history chronic obstructive pulmonary disease lung disease ( e.g. , asthma ) could cause CO2 retention . Who clinically significant abnormal find physical exam , medical history clinical laboratory result screen . Who history allergic adverse response study drug relate drug . Who start significantly restrictive diet four week precede first dose study medication ( qualify session ) . Who donate blood plasma within 30 day prior first dose study medication . Male subject hemoglobin less 125 g/L female subject hemoglobin less 115 g/L . Who participate another clinical trial within 30 day prior first dose study medication ( qualify session ) . Who use overthecounter ( OTC ) medication , include vitamin natural health product , within seven day prior first dose study medication ( qualify session ) without evaluation approval study investigator . Who use prescription medication , except hormonal contraceptive hormonal replacement therapy , within seven day prior first dose study medication ( qualify session ) without evaluation approval study investigator . Who history glaucoma pupil abnormality opinion qualify investigator designee could interfere ability perform pupillometry . Who able abstain nicotine smoke clinical unit Who positive test treat hepatitis B , hepatitis C HIV . Who current pending legal charge . Who , opinion investigator , consider suitable unlikely comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>ALO-01</keyword>
	<keyword>morphine</keyword>
	<keyword>Determination relative pharmacodynamic effect</keyword>
	<keyword>( include drug-liking ) , pharmacokinetics , safety</keyword>
	<keyword>ALO-01 administer whole crushed compare</keyword>
	<keyword>equivalent dos immediate release morphine placebo</keyword>
</DOC>